Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Shares Issued (2016 - 2025)

Standard Biotools (LAB) has disclosed Shares Issued for 15 consecutive years, with -$202000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Shares Issued fell 150.88% to -$202000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was -$202000.0, a 113.32% decrease, with the full-year FY2024 number at $918000.0, up 26.97% from a year prior.
  • Shares Issued was -$202000.0 for Q4 2024 at Standard Biotools, down from $68000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $20.1 million in Q3 2020 to a low of -$400000.0 in Q3 2022.
  • A 5-year average of $2.3 million and a median of $234500.0 in 2023 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: skyrocketed 80800.0% in 2021, then crashed 150.88% in 2024.
  • Standard Biotools' Shares Issued stood at $1000.0 in 2020, then surged by 80800.0% to $809000.0 in 2021, then decreased by 10.63% to $723000.0 in 2022, then tumbled by 45.09% to $397000.0 in 2023, then plummeted by 150.88% to -$202000.0 in 2024.
  • Per Business Quant, the three most recent readings for LAB's Shares Issued are -$202000.0 (Q4 2024), $68000.0 (Q3 2024), and $980000.0 (Q2 2024).